GlobeNewswire

Octo Health Launches Beta to Make Proactive, Personalized Healthcare More Accessible
05/11/2026
Octo Health brings medical records, lab results, medications and health data into one health timeline, giving consumers a more complete picture of their health By combining annual testing of more than 100 biomarkers [...]
John Patrick University and Advanced Imaging Review Launch “Grow Your Own” Program to Build Healthcare Imaging Talent
05/11/2026
New initiative addresses radiology shortage and helps hospitals and health systems develop existing employees into radiologic technologists and advanced imaging professionals while they continue working SOUTH BEND, Ind [...]
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
05/11/2026
Provides funding needed to complete HCW9302 Phase 1 study in alopecia areata and establish Recommended Phase 2 Dose MIRAMAR, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics [...]
REMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026
05/11/2026
Board of Directors Recommends a Vote FOR Each Proposal, Including a Reverse Stock Split Authorization Intended to Provide Flexibility to Regain Compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement Stockholders [...]
Sparrow Pharmaceuticals Announces Expansion Cohorts in Phase 2b CAPTAIN-T2D Trial to Evaluate Clofutriben Across the Full Range of Cortisol Levels in Difficult-to-Control Type 2 Diabetes
05/11/2026
CAPTAIN-T2D remains on track, with topline data from the original and expansion cohorts expected by end-of-year (EOY) 2027 to enable pivotal Phase 3 readiness BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sparrow [...]
Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
05/11/2026
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey [...]
Dogwood Therapeutics Announces Third Quarter 2026 Financial Results
05/11/2026
- Completed the Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 - - Phase 2b Long-Term Extension Study fully recruited, 95 patients enrolled, assessing [...]
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints Bitopertin NDA resubmission planned by end of 2026, with an FDA decision for [...]
Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results
05/11/2026
– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target –Announces [...]
Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion
05/11/2026
HINGHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, today announced that the Canadian Intellectual [...]
Prenetics’ IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics
05/11/2026
Care Bears by IM8 to launch, with great-tasting, science-backed gummy multivitamins for kids and adults in 1H 2027 Enters a global gummy supplements market projected to nearly double to ~US$47.8 billion by 2030 IM8 to [...]
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
05/11/2026
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage [...]
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
05/11/2026
Completed Phase 1 study of SCY-770, a first-in-class, highly selective, oral direct AMPK activator for the treatment of ADPKD; Phase 2 proof-of-concept trial to initiate in Q4 2026 Awarded BARDA contract providing up to [...]
Annovis Announces Pricing of $21.0 Million Public Offering
05/11/2026
MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
05/11/2026
FALLS CHURCH, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the [...]
LightSolver Secures ~$1.8 Million Grant from Israel’s Innovation Authority to Advance its Laser Processing Unit (LPU)
05/11/2026
Government-backed R&D program to advance next-generation LPU hardware and expand the LPU Lab platform Builds on LightSolver’s recent commercial and technical momentum, including the strategic partnership with Boeing [...]
Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
05/11/2026
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable [...]
Incyclix Bio Establishes Steering Committee of Leading Breast Cancer Experts to Guide INX-315 Clinical Development
05/11/2026
Appointment of distinguished oncology leaders comes as Incyclix prepares for a potential pivotal trial in 2027 RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell [...]
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
05/11/2026
SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum